Effects of size and sequence on the iontophoretic delivery of oligonucleotides.

Adequate cellular availability of synthetic oligonucleotides is crucial to their success as therapeutic agents. These compounds, however, are not expected to be orally active. This has led to interest in a variety of alternate drug delivery methods, including iontophoretically enhanced transdermal delivery. The purpose of this work is to begin characterizing the structure-activity relationship for iontophoresis of oligonucleotides through the skin. The in vitro permeation of 16 biologically relevant phosphorothioate oligonucleotides across hairless mouse skin was studied. Oligonucleotides with less than 20 bases (n = 10) had a wide range of steady-state flux levels (2.1-26.2 pmol/ cm2 h). A lower flux differential was observed for compounds ranging from 20 to 40 bases long (1.2-2.2 pmol/cm2 h). For the smaller compounds, transport, in general, decreased with increasing size; however, there were several oligonucleotides that did not follow this pattern. These data indicate that factors other than size influence transport and that the impact is greater at shorter lengths. Differential penetration between equal sized oligonucleotides synthesized with identical bases in reversed order indicates that sequences and not simply base composition affects steady-state flux across skin. Molecular structure, therefore, is a key contributor to iontophoretically assisted transport. Further studies are necessary to develop more precise predictions about the relationship between oligonucleotide structure and transdermal delivery.

[1]  X. Li,et al.  Sensitization of multidrug-resistant human leukemia cells with MDR1-targeted antisense and inhibition of drug-mediated MDR1 induction , 1997, Leukemia.

[2]  P. Iversen,et al.  A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo. , 1997, Toxicology and applied pharmacology.

[3]  A. Branch.  A Hitchhiker's guide to antisense and nonantisense biochemical pathways , 1996, Hepatology.

[4]  P. G. Green.  Iontophoretic delivery of peptide drugs , 1996 .

[5]  P. Iversen,et al.  Inhibition of the rat cytochrome P450 3A2 by an antisense phosphorothioate oligodeoxynucleotide in vivo. , 1995, The Journal of pharmacology and experimental therapeutics.

[6]  et al.,et al.  The RNA component of human telomerase , 1995, Science.

[7]  K. Oldenburg,et al.  Iontophoretic delivery of oligonucleotides across full thickness hairless mouse skin. , 1995, Journal of pharmaceutical sciences.

[8]  C. Hunt,et al.  Characteristics of oligonucleotide uptake in human keratinocyte cultures. , 1993, The Journal of investigative dermatology.

[9]  J. Feigon,et al.  Strand orientation in the DNA quadruplex formed from the Oxytricha telomere repeat oligonucleotide d(G4T4G4) in solution. , 1993, Biochemistry.

[10]  V. Vlassov,et al.  Penetration of oligonucleotides into mouse organism through mucosa and skin , 1993, FEBS letters.

[11]  K. Isenberg,et al.  Oligonucleotide Pharmacotherapy: An Antigene Strategy , 1993, Pharmacotherapy.

[12]  P. Iversen.  In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue. , 1991, Anti-cancer drug design.

[13]  V. Vlassov,et al.  Iontophoretic delivery of oligonucleotide derivatives into mouse tumor. , 1994, Antisense research and development.

[14]  P. Iversen,et al.  Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. , 1994, Antisense research and development.